Fund Information / Factsheet • Oct 25, 2022
Fund Information / Factsheet
Open in ViewerOpens in native device viewer
Discrete year
30/9/2021 to
30/9/2020 to
Please note that this chart could include dividends that have been declared but not yet paid.
| Performance over (%) |
10y | 5y | 3y | 1y | 6m | |
|---|---|---|---|---|---|---|
| Share price (Total return) |
88.3 | 12.2 | 4.2 | 2.2 | -7.3 | |
| Net asset value (Total return) |
94.0 | 12.9 | 4.5 | 1.2 | -7.2 | |
| Benchmark (Total return) |
79.5 | 11.3 | 2.4 | -4.0 | -8.3 | |
| Relative NAV (Total return) |
14.5 | 1.6 | 2.1 | 5.2 | 1.1 |
The Company underperformed the FTSE All Share Index during the month.
The biggest contributing sector was pharmaceuticals, helped principally by Merck and Johnson & Johnson. The aerospace & defence sector also contributed positively, largely driven by BAE Systems. The biggest detracting stocks were M&G (fund manager and life assurer) and Phoenix (life assurer).
Monetary tightening is a headwind for equity markets. However, the dividend yield of UK equities is attractive compared with the average of global equities.
References made to individual securities do not constitute a recommendation to buy, sell or hold any security, investment strategy or market sector, and should not be assumed to be profitable. Janus Henderson Investors, its affiliated advisor, or its employees, may have a position in the securities mentioned.
The Company's objective is to provide long-term growth in income and capital, principally by investment in equities listed on the London Stock Exchange. The Board fully recognises the importance of dividend income to shareholders.
Renowned for its record-setting annual dividend increases since 1966, the Company targets longterm income and capital growth.
| NAV (cum income) | 370.2p | ||
|---|---|---|---|
| NAV (ex income) | 364.2p | ||
| Share price | 376.5p | ||
| Discount(-)/premium(+) | 1.7% | ||
| Yield | 5.21% | ||
| Net gearing | 8% | ||
| Net cash | - | ||
| Total assets Net assets |
£1,828m £1,727m |
||
| Market capitalisation | £1,756m | ||
| Total voting rights | 466,454,868 | ||
| Total number of holdings | 86 | ||
| Ongoing charges (year end 30 June 2022) |
0.37% | ||
| Overall Morningstar RatingTM |
| ||
| Benchmark | FTSE All Share Index | ||
| Source: BNP Paribas for holdings information and Morningstar for all |
Source: BNP Paribas for holdings information and Morningstar for all other data. Differences in calculation may occur due to the methodology used.
Please note that the total voting rights in the Company does not include shares held in Treasury.
| 30/9/2019 to 30/9/2020 |
-21.06 | -18.44 |
|---|---|---|
| 30/9/2018 to 30/9/2019 |
3.79 | 3.72 |
| 30/9/2017 to 30/9/2018 |
3.71 | 4.14 |
performance (%) Share price NAV
30/9/2022 2.21 1.20
30/9/2021 29.14 26.61
All performance, cumulative growth and annual growth data is sourced from Morningstar.
Source: at 30/09/22. © 2022 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.
Please remember that past performance does not predict future returns. The value of an investment and the income from it can rise as well as fall as a result of market and currency fluctuations, and you may not get back the amount originally invested.
How to invest Go to www.janushenderson.com/howtoinvest Find out more Go to www.cityinvestmenttrust.com
Key information
| Top 10 holdings | (%) |
|---|---|
| British American Tobacco | 4.6 |
| Shell | 4.1 |
| Diageo | 4.0 |
| BAE Systems | 3.4 |
| RELX | 3.1 |
| BP | 3.0 |
| AstraZeneca | 2.8 |
| Unilever | 2.8 |
| Imperial Brands | 2.7 |
| HSBC | 2.6 |
Geographical focus (%) United
The above geographical breakdown may not add up
to 100% as this only shows the top 10.
| Stock code | CTY | |
|---|---|---|
| AIC sector | AIC UK Equity Income | |
| Benchmark | FTSE All Share Index | |
| Company type | Conventional (Ords) | |
| Launch date | 1891 | |
| Financial year | 30-Jun | |
| Dividend payment | November, February, May, August |
|
| Risk rating (Source: Numis) |
Average | |
| Management fee | 0.325% per annum of net assets |
|
| Performance fee | No | |
| (See Annual Report & Key Information Document for more information) | ||
| Regional focus | UK | |
| Fund manager appointment |
Job Curtis 1991 |
References made to individual securities do not constitute a recommendation to buy, sell or hold any security, investment strategy or market sector, and should not be assumed to be profitable. Janus Henderson Investors, its affiliated advisor, or its employees, may have a position in the securities mentioned.
All performance, cumulative growth and annual growth data is sourced from Morningstar
Please remember that past performance does not predict future returns. The value of an investment and the income from it can rise as well as fall as a result of market and currency fluctuations, and you may not get back the amount originally invested.
How to invest Go to www.janushenderson.com/howtoinvest Customer services 0800 832 832
10 year return of £1,000
Investment environment
The UK equity market, as measured by the FTSE All Share Index, produced a negative total return of 5.9% as concerns about a cooling economy and government plans for unfunded tax cuts unnerved investors. The "mini budget" led to a sharp rise in gilt yields. Sterling fell by 4% against the US dollar to end the month at an exchange rate of 1.12. The more domestically biased FTSE 250 Index of medium-sized companies underperformed with a fall of 9.7%, compared with a fall of 5.2% for the FTSE 100 Index of the largest companies.
The Company's net asset value fell 5.9% while the FTSE All Share Index fell 5.9%.
The pharmaceutical sector, where a large proportion of sales are made in the US, was a notable contributor with strong performance from our holdings in Merck and Johnson & Johnson. BAE Systems, the UK's leading defence contractor which also has significant operations in the US also contributed positively. The rise in its share price reflected the outlook for spending on defence equipment. Against a backdrop of turmoil in the bond market, financial group M&G and life assurer Phoenix were notable detractors, despite their attractive dividend yields. Tesco also underperformed, although it reported satisfactory half-year results in October.
During the month, we made additions to employment agency
Hays, which is well diversified geographically, with sales split between the UK, Germany, and Australia. We sold the final part of our holding in Brewin Dolphin, the private client wealth manager, ahead of the completion of the takeover, and reinvested the proceeds in Rathbones (in the same sector).
The determination of central banks to tame inflation through interest rate increases and quantitative tightening is a headwind for markets. In the UK, the rise in mortgage rates on top of the energy price increases could lead to a squeeze on consumer spending. However, on the positive side, the fall in sterling has a positive effect on the translation of profits for the many UK-listed companies with overseas operations. The dividend yield of UK equities also looks attractive compared with the global equity average.
Source: Bloomberg as at 30 September 2022
The amount by which the price per share of an investment trust is either lower (at a discount) or higher (at a premium) than the net asset value per share (cum income), expressed as a percentage of the net asset value per share.
The effect of borrowing money for investment purposes (financial gearing). The amount a company can "gear" is the amount it can borrow in order to invest. Gearing is used in the expectation that the returns on the investments bought will exceed the costs of the borrowings that funded the purchase. This Company can also use synthetic gearing through derivatives and foreign exchange hedging and/or other non-fully funded instruments or techniques.
The company's leverage is the sum of financial gearing and synthetic gearing. Details of the Company's leverage limits can be found in both the Key Information Document and Annual Report. Where a company utilises leverage, the profits and losses incurred by the company can be greater than those of a company that does not use leverage.
Month end closing mid-market share price multiplied by the number of shares outstanding at month end.
The value of investments and cash, including current year revenue, less liabilities (prior charges such as loans, debenture stock and preference shares at fair value).
The value of investments and cash, excluding current year revenue, less liabilities (prior charges such as loans, debenture stock and preference shares at fair value).
The theoretical total return on shareholders' funds per share reflecting the change in Net Asset Value (NAV) assuming that dividends paid to shareholders were reinvested at NAV at the time the shares were quoted ex-dividend. A way of measuring investment management performance of investment trusts which is not affected by movements in discounts/premiums.
Total assets minus any liabilities such as bank loans or creditors.
A company's net exposure to cash/cash equivalents expressed as a percentage of shareholders' funds, after any offset against its gearing. This is only shown for companies that have gearing in place.
A company's total assets (less cash/cash equivalents) divided by shareholders' funds expressed as a percentage.
The total expenses for the financial year (excluding performance fee), divided by the average daily net assets, multiplied by 100.
The key measure used to assess risk is volatility of returns, using historic net asset value (NAV) performance of the company over 1 and 3 years. In this instance volatility measures how much a Company's NAV fluctuates over time in relation to the UK Equity market. The higher a volatility figure, the more the NAV has fluctuated (both up and down) over time. Please note that risk categorisations are indicative and based principally on historic data and should not be solely relied upon when making investment decisions.
Closing mid-market share price at month end.
The theoretical total return to the investor assuming that all dividends received were reinvested in the shares of the company at the time the shares were quoted ex-dividend. Transaction costs are not taken into account.
Cum Income NAV multiplied by the number of shares, plus prior charges at fair value.
Calculated by dividing the current financial year's dividends per share (this will include prospective dividends) by the current price per share, then multiplying by 100 to arrive at a percentage figure.
A defensive stock is a stock that provides consistent dividends and stable earnings regardless of the state of the overall stock market. There is a constant demand for their products, so defensive stocks tend to be more stable during the various phases of the business cycle.
The rate at which the prices of goods and services are rising in an economy. The CPI and RPI are two common measures.
Gilt yields express the return on a gilt (government bond) as an annual percentage. There are two ways to do this. The income yield just looks at the annual coupon as a percentage of the price. So if the annual coupon is, say, £5 and the price is £90, the income yield is (5/90) x 100%, or 5.5%. This is useful to investors only interested in the income return.
Quantitative tightening (QT) refers to monetary policies that contract, or reduce, the Federal Reserve System (Fed) balance sheet. This process is also known as balance sheet normalization. In other words, the Fed (or any central bank) shrinks its monetary reserves by either selling Treasury's (government bonds) or letting them mature and removing them from its cash balances. This removes liquidity, or money, from financial markets.
www.janushendersoninvestmenttrusts.com
Overall Morningstar Rating™ is a measure of a fund's risk-adjusted return, relative to similar funds. Fund share classes are rated from 1 to 5 stars, with the best performers receiving 5 stars and the worst performers receiving a single star. Overall Morningstar Rating™ is shown for Janus Henderson share classes achieving a rating of 4 or 5. Ratings should not be taken as a recommendation. For more detailed information about Morningstar Ratings, including its methodology, please go to global.morningstar.com/managerdisclosures.
Not for onward distribution. Before investing in an investment trust referred to in this document, you should satisfy yourself as to its suitability and the risks involved, you may wish to consult a financial adviser. This is a marketing communication. Please refer to the AIFMD Disclosure document and Annual Report of the AIF before making any final investment decisions. Past performance does not predict future returns. The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested. Tax assumptions and reliefs depend upon an investor's particular circumstances and may change if those circumstances or the law change. Nothing in this document is intended to or should be construed as advice. This document is not a recommendation to sell or purchase any investment. It does not form part of any contract for the sale or purchase of any investment. [We may record telephone calls for our mutual protection, to improve customer service and for regulatory record keeping purposes.]
Issued in the UK by Janus Henderson Investors. Janus Henderson Investors is the name under which investment products and services are provided by Janus Henderson Investors International Limited (reg no. 3594615), Janus Henderson Investors UK Limited (reg. no. 906355), Janus Henderson Fund Management UK Limited (reg. no. 2678531), Henderson Equity Partners Limited (reg. no.2606646), (each registered in England and Wales at 201 Bishopsgate, London EC2M 3AE and regulated by the Financial Conduct Authority) and Janus Henderson Investors Europe S.A. (reg no. B22848 at 2 Rue de Bitbourg, L-1273, Luxembourg and regulated by the Commission de Surveillance du Secteur Financier).
Janus Henderson, Knowledge Shared and Knowledge Labs are trademarks of Janus Henderson Group plc or one of its subsidiaries. © Janus Henderson Group plc
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.